At a glance
ClinicalIndex Comparison RecordPhase 2Completed· 241 enrolled
Drug / intervention
Paclitaxel +2 moredrug
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.
Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
A Phase 2, Randomized Study of MLN0128 (a Dual TORC1/2 Inhibitor), MLN0128+MLN1117 (a PI3Kα Inhibitor), Weekly Paclitaxel, or the Combination of Weekly Paclitaxel and MLN0128 in Women With Advanced, Recurrent, or Persistent Endometrial Cancer
In Brief
A Phase 2 clinical trial evaluating Paclitaxel, Sapanisertib, and 1 other intervention for Endometrial Neoplasms. Completed, enrolled 241 participants across 78 sites in 10 countries.
Detailed Summary
The primary purpose of this study is to determine if sapanisertib in combination with weekly paclitaxel improves progression-free survival (PFS) compared to weekly paclitaxel alone.
Study Details
Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsEndometrial Neoplasms
CountriesAustralia, Belgium, Canada, Germany, Italy, Netherlands, Norway, Spain, United Kingdom, United States
Timeline
Phase 2CompletedFinished
20162017201820192020202120222023202420252026
First PostedMar 2016
Enrollment StartApr 2016
Primary CompletionJul 2019
Study CompletionOct 2020
TodayJul 2026
First PostedMar 31, 2016
Enrollment StartApr 1, 2016
Primary CompletionJul 2, 2019
Study CompletionOct 30, 2020
TodayJul 2, 2026
Enrollment to primary: 3.3 yearsPosted 10.3 years ago
Interventions
Paclitaxeldrug
Paclitaxel intravenous solution.
Sapanisertibdrug
Sapanisertib capsules.
MLN1117drug
MLN1117 capsules.